FDA demands another trial for artificial skin
This article was originally published in Clinica
The FDA has told the maker of Dermagraft that it must start a new trial of the artificial skin in the US before it can be approved for diabetic foot ulcer patients. This is despite a conditional recommendation for approval from an advisory panel early this year. The move could set back sales of the skin for this application by as much as two years.